CCL2 and obesity disorder: showed that treatment with liraglutide, compared to dietary restriction-based weight loss, increased adipose tissue inflammation, measured as CD14, MCP-1, TNF and IL-6 gene expression and concluded that despite a stronger improvement of glycemic control, liraglutide was not effective in amelioration of obesity-associated adipose tissue dysfunction [31].